Newron Pharmaceuticals (SIX: NWRN)

Last close As at 22/02/2024


−0.02 (−0.25%)

Market capitalisation


Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh


Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber


Balance Sheet

Forecast net cash (€m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 11.202 68.182 19.006
Relative 8.495 58.668 17.48
52 week high/low CHF10.4/CHF3.9


Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). A potentially pivotal Phase III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS is ongoing; readouts are expected in March 2024. For the Phase II trial (study 014/015) in patients with TRS, encouraging final results (12-month data for the full patient cohort) were announced in January 2024, which showed that evenamide was both safe and efficacious. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. Newron intends to begin an additional, potentially pivotal, multinational Phase III programme in TRS patients (expected to start in Q124). In its H123 results, Newron recorded total revenue of €5.5m for the period, nearly double H122’s revenue of €2.8m, primarily driven by higher royalty income for Xadago.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2021A 5.8 (11.4) (14.1) (79.23) N/A N/A
2022A 6.1 (12.6) (17.0) (95.34) N/A N/A
2023E 8.9 (11.7) (14.6) (81.90) N/A N/A
2024E 6.8 (19.1) (22.3) (124.77) N/A N/A

Further insights



Newron Pharmaceuticals: EKF 2023 QuickView



Deutsches Eigenkapitalforum (EKF) 2022 healthcare



Deutsches Eigenkapitalforum (EKF) 2022

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free